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1. Background
Hepatitis C is a liver disease caused by the hepati-
tis C virus. The virus is blood-borne and becomes con-
tagious via unsafe injection practices, unsafe blood
and blood product transfusions, and inadequate sterili-
zation of medical equipment (1). Approximately
350,000 to 500,000 people die each year from hepati-
tis C-related liver diseases (2). Diagnosis of the chron-
ic HCV infection is based on anti-HCV screening
assays and a nucleic acid test for confirming chronic
infection (1). The current standard treatment for hepa-
titis C is combination of antiviral therapy with interfer-
on and ribavirin (1). There is currently no vaccine for
the disease.
HCV is an RNA virus that is directly translated to a
precursor polyprotein. The precursor is cleaved by
host and viral proteases to produce four structural
(core protein, E1, E2, and P7) and six non-structural
(NS2, NS3, NS4A, NS4B, NS5A, and NS5B) viral
proteins (3). Among these proteins, NS4B is studied
relatively less than the others. A variety of functions
have been suggested for NS4B, of which the most sig-
nificant is providing a scaffold for the assembly of the
HCV replication complex (4).
NS4B is among the HCV major immunogenic pro-
teins in chronic infection (5). Some of the diagnosti-
cally important antigenic epitopes have been found to
reside within NS4B (6-8). There are two FDA-
approved commercially available enzyme immunoas-
says (EIA) for screening anti-HCV antibodies: Abbott
HCV EIA 2.0 and ORTHO HCV Version 3.0 enzyme-
linked immunosorbent assay (ELISA) Test System.
Use of recombinant NS4B is a requirement in both
EIAs. Hence, high level expression and purification of
NS4B is essential for designing appropriate HCV sero-
diagnostic assay.
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Background: Detection of hepatitis C virus specific antibodies is the initial step in chronic HCV diagnosis. HCV NS4B
is among the most immunogenic HCV antigens and has been widely used in commercial Enzyme Immunoassays (EIA).
Additionally, NS4B, a key protein in the virus replication, can be an alternative target for antiviral therapy.
Objectives: Development of a new method for high-level expression and purification of NS4B coding region was the aim
of the report.
Materials and Methods: Viral RNA was purified from the serum of an HCV positive patient and NS4B coding region
was amplified using nested RT-PCR. PCR products were cloned into pET102/D-TOPO expression vector and transformed
into E. coli BL21. Induction was performed by adding 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) to the culture
medium. Immunoreactivity of the purified recombinant proteins was evaluated by immunoblotting and indirect enzyme-
linked immunosorbent assay (ELISA).
Results: The recombinant NS4B protein was expressed and its immunoreactivity was confirmed by ELISA and western
blotting.
Conclusions: The directional TOPO cloning provides an efficient and easy platform for heterologous expression of
immunoreactive HCV NS4B.
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Although the HCV standard treatment with a com-
bination of interferon and ribavirin is successful for
many patient populations, this regimen has numerous
limitations, including non-response, relapse, poor tol-
erability and long duration of treatment (9). To com-
pensate for the limitations, pharmacological studies
with the aim of finding new therapeutic targets are
needed to be done. NS4B is among the key proteins in
the viral life-cycle, and ironically it is among the least
characterized of the HCV structural and nonstructural
proteins (10). Therefore, pharmacological studies on
NS4B are required to evaluate the effect of targeting
NS4B as an alternative target for direct-acting antivi-
ral agents. Meanwhile, high level expression and
purification of NS4B could facilitate studies on drug
design and development. 
Here, a new method was described for substantial
expression and purification of recombinant NS4B
using pET102/D-TOPO expression vector and E. coli
BL21 as the host. The immuno reactivity of the recom-
binant antigen was evaluated by western blot analysis
and ELISA using HCV positive human sera.
2. Materials and Methods
2.1. Human Sera
HCV-positive (100 samples) and HCV-negative (50
samples) were collected from Iranian Blood
Transfusion Organization. All sera were tested for the
presence of anti-HCV antibody using thirdgeneration
ELISA kit (Hepanostika HCV Ultra, BioMerieux,
Marcy I’Etoile, France). Positive results of HCV anti-
body were confirmed by recombinant immunoblot
assay (RIBA). Infecting HCV genotype was deter-
mined using HCV genotyping kit (Sacace, Como,
Italy).
2.2. HCV RNA Extraction and cDNA Synthesis
HCV RNA was extracted from the serum of a
patient infected with HCV genotype 1a usingHighPure
Viral RNA MiniKit (Roche Applied Biosystems,
Frankfurt, Germany) according to the manufacturer’s
instructions. The extracted RNA was reverse tran-
scribed into cDNA using reverse transcriptase
enzymes l Maloney Maurine Leukemia Virus
((MMLV)(New England Biolabs, Ipswich, MA,
USA)) (NEB#M0253USA) according to the manufac-
turer’s protocol.
2.3. Nested PCR for Amplification of NS4B Coding
Region
Coding region of NS4B was amplified by nested
PCR. Designed forward and reverse outer primers were
5′GAGGTCCTCTACCGGGAGTTCG3′ and 5′CCA GTC-
CCAGATGTCCCTTAGCCA3′. Designed forward and
reverse inner primers were 5′CACCTCCC AGCACT-
TACCGTAC3′ and 5′GACACACGTGTTGCA GTCTAT-
CA3′. To enable insertion of blunt end PCR product into
TOPO cloning vector in the right orientation, the inner
forward primer contained the sequence CACC at the
5′end. The first PCR reaction was assembled in a final
volume of 25 μL using the following reagents: 0.7 μL
Pfu DNA polymerase (2.5 U.μL-1; Stratagene, La Jolla,
CA, USA), 1 μL (100 ng.μL-1) of each of the forward
and reverse outer primers, 2.5 μL of 10× reaction buffer,
2 μL dNTPs (10 mM) and 3 μL template (cDNA 100
ng.μL-1). The second PCR reaction was performed on
the product of the first PCR (3 μL template) using inner
primers as described for the first PCR. Thermal cycling
conditions except for the annealing step were similar for
the first and the second PCR and as follows: initial
denaturation (95°C for 3 min), 35 cycles of denaturation
(95°C for 45 seconds), annealing (the first PCR: 58°C
for 30 seconds and the second PCR: 62°C for 30 sec-
onds), extension (72°C for 1 min), and the final exten-
sion (72°C for 10 min).
2.4. Construction of NS4B Plasmid (TOPO Cloning)
After agarose gel electrophoresis, PCR products
with correct size were extracted from the gel using
High Pure PCR Product Purification Kit (Roche,
Frankfurt, Germany) according to the manufacturer’s
protocol. The purified PCR products were ligated into
pET102/D-TOPO expression vector (Invitrogen,
Montreal, Canada) according to the manufacturer’s
instructions.  The ligation products were transformed
into E. coli BL21 (DE3) strain (Invitrogen, Montreal,
Canada) and cultured in Luria Bertani (LB) agar plate
containing 100 μg.μL-1 of ampicillin. Plasmids were
extracted from colonies on agar plate using High Pure
Plasmid Isolation Kit (Roche, Frankfurt, Germany)
according to the manufacturer’s instructions. To con-
firm the accuracy of the construct, colony PCR and
DNA sequencing (Bioneer, Daejeon, South Korea)
were performed on extracted plasmids.
2.5. Expression of Recombinant NS4B
E. coli BL21 (DE3) cells carrying recombinant plas-
mid were grown in 10 μL LB broth containing
100 μg.μL-1 ampicillin at 37°C with gentle shaking (150
rpm) overnight. Once the optical density (OD) of the cul-
ture reached 0.6 at 600 nm, induction was performed
using 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG)
(Invitrogen, Frankfurt, Germany). The culture was left to
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grow at 37°C with gentle shake for 4 h. Cells were har-
vested by centrifugation at 5,000 rpm at 4°C for 10 min.
2.6. Purification of Recombinant NS4B
Ni-NTA Purification System (Invitrogen, Frankfurt,
Germany) was used to purify recombinant NS4B
according to the user manual. The harvested cells were
subjected to cell lysis under denaturing conditions. The
cell pellet from a 50 μL culture was resuspended in 8 μL
Guanidinium Lysis Buffer (containing 6 M guanidine
hydrochloride, 20 mM sodium phosphate, and 0.5 M
NaCl) for 10 min on a shaker. The cell lysate was soni-
cated on ice with three 5-second pulses at high intensi-
ty. The lysate was centrifuged at 3,000 ×g for 15 min
and the supernatant was purified using Ni-NTA purifi-
cation system. A volume of 8 μL of the lysate was
applied to the purification column and incubated for 30
min with gentle agitation. The column was centrifuged
and the supernatant was removed. The column was
washed twice with 4 μL Denaturing Binding Buffer
pH 6.0. Then the column was washed twice with 4 μL
Denaturing Wash Buffer pH 5.3. The recombinant pro-
tein was eluted with 5 μL Denaturing Elution Buffer.
The fractions were subsequently quantified by Micro
BCA protein assay kit (Pierce, Rockford, IL, USA)
according to the user’s guide.
2.7. Western Blot
An amount of 25 μg of protein was separated on
10% SDS-PAGE gel and transferred onto PVDF mem-
brane (Amersham, London, United Kingdom). The
membrane was blocked for 1.5 h with 5% skim milk in
TBST buffer (Tris-Buffered Saline containing 0.1%
v/v Tween 20), the membrane was incubated at 4ºC
overnight with a pool of HCV positive sera (contain-
ing antibodies to 1a, 1b, and 3a HCV genotypes) dilut-
ed 1:15000 in 3% skim milk in TBS buffer. The mem-
brane was washed for 15min wash and three 5-min
washes with TBST buffer. Membrane was incubated
withHRP-conjugated anti-human IgG (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) diluted
1:100,000 in 3% skim milk in TBS buffer for 1 h at
room temperature. After washing (as described previ-
ously), the signals were detected by chemilumines-
cence using the ECL detection reagent (GE
Healthcare, Piscataway, NJ, USA). 
In a parallel experiment, western blot analysis was
performed using anti-His tag monoclonal antibody
(Invitrogen, Frankfurt, Germany) diluted 1:2000 in 3%
skim milk in TBS buffer. This antibody specifically
binds to poly-histidine tag of the recombinant protein
and confirms the presence of the recombinant NS4B.
2.8. ELISA
Each ELISA well was incubated with 100 μL of the
purified recombinant NS4B in 0.1 M sodium carbon-
ate buffer pH 9.6 (40 μg.μL-1), at 4°C overnight. Wells
were incubated with blocking buffer (1% BSA in phos-
phate buffer saline) at 22°C for 1 h. After 3 washes
with wash buffer (phosphate buffer saline containing
0.1% Tween-20), 40 HCV positive sera fromdifferent
HCV genotypes (1a, 1b, and 3a), each separately dilut-
ed 1:1000 in PBS containing 0.1% (v/v) Tween-20 and
0.01% (w/v) BSA, was added to the wells and incubat-
ed at 37°C for 30 min. Sera from 40 healthy individu-
als were similarly used as negative control. After 3
washes, 100 μL of HRP-conjugated rabbit anti-human
IgG (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) diluted 1:100,000 was added to each well and
incubated at 37°C for 30 min. After 3 washes, 100 μL
of TMB substrate (Roche Diagnostics, Sussex, UK)
was added to each well and incubated for 15 min at
22°C. The reaction was stopped by adding 50 μL of
0.2 M H2SO4 and the absorbance was measured at 450
nm with ELISA reader (Biochrome, Cambridge, UK).
3. Results
3.1. Gene Amplification, TOPO Cloning and
Transformation
Amplification of HCV NS4B protein coding
sequence was performed successfully by nested RT-
PCR. Electrophoresis of the PCR products showed a
single clear band equal to 800 bp (Figure 1). The accu-
racy of the recombinant plasmid was confirmed by
colony PCR and sequencing. The efficiency of bacter-
ial transformation was approved by colony formation
on LB agar plate containing 100 mg.μL-1 ampicillin.
3.2. Analysis of NS4B Expression by SDS-PAGE,
Protein Assay and Western Blot
SDS-PAGE showed successful expression of the
recombinant NS4B after IPTG induction (Figure 2). It
was determined that the molecular weight of the
recombinant NS4B was about 44 kDa. Protein purifi-
cation using Ni-NTA purification system yielded high-
ly pure fractions of recombinant protein near to homo-
geneity, as observed by SDS-PAGE (data not shown)
and the recombinant protein concentrations in the elut-
ed fractions were as high as 48 μg.μL-1. Western blot
analysis using anti-His antibody confirmed the authen-
ticity of the recombinant protein (Figure 3) and
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Western blot analysis using human sera from HCV-
infected patients confirmed the immunoreactivity of
the recombinant protein (Figure 4).
3.3. ELISA
ELISA was performed on 40 HCV negative sera and
40 HCV positive sera from different HCV genotypes
(1a, 1b, and 3a). The optimum cutoff value (0.78) was
calculated as the mean OD value of negative samples
plus three times the standard deviation. The ELISA
showed 85% sensitivity and 80% specificity.
4. Discussion
The HCV non-structural 4B (NS4B) protein is a
27 kDa hydrophobic protein localized in the endoplas-
mic reticulum membrane (11) and it is mainly
involved in HCV replication (4). NS4B is amongthe
HCV major immunogenic proteins and it is widely
used in anti-HCV antibody detection in diagnostic
serologic tests (6-8). Furthermore, since NS4B is a key
protein in virus life cycle, it provides new opportuni-
ties for antiviral intervention against a leading cause of
liver diseases worldwide (12). Therefore, rapid, high
yield, and economical production of recombinant
HCV NS4B is essential for producing HCV diagnostic
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Figure 2. SDS-PAGE analysis of recombinant-NS4B fusion
protein. Lane M: Protein marker; lane1: E. coli BL21 cell
lysate harboring recombinant plasmid before induction with
IPTG; lane 2: E. coli BL21 cell lysate harboring recombi-
nant plasmid after induction with IPTG (44 kDa)
Figure 3. Western blot analysis of the recombinant NS4B
protein with mouse anti-HIS antibodies. Lane M: Protein
marker; lane 1: purified NS4B (44 kDa); lane 2: fraction
from wash step of Ni-NTA purification; lane 3:  total protein
of E. coli BL21carrying pET102-NS3 without IPTG induc-
tion; lane 4: Total protein of Escherichia coli BL21 as neg-
ative control  
Figure 4. Western blot
analysis of the recombi-
nant NS4B protein with
HCV-positive human sera.
Lane 1: Protein marker;
lane 2: purified NS4B (44
kDa)
Figure 1. PCR amplification of
HCV NS4B coding sequence.
Lane 1: the amplified product of
HCV NS4B by pfuDNA poly-
merase (800 bp); lane 2: DNA
marker (100 bp) 
kits. Moreover, biochemical characterization of the
protein, and development of anti-HCV drugs are all
dependent on having enough protein that can be
obtained via heterologous expression. 
NS4B has often been expressed in insect cells using
baculovirus vector (5, 13-15). In the present work, we
described the expression and purification of recombi-
nant HCV NS4B coding region in E. coli BL21 using
pET102/D-TOPO expression vector and evaluated its
immunoreactivity. To the best of our knowledge, this is
the first time that HCV NS4B has been produced using
directional TOPO cloning.
Directional TOPO vectors in general provide a fast
and easy method for cloning and expression of recom-
binant proteins. These vectors take advantage from
T7lac promoter for high-level, IPTG-inducible expres-
sion of the gene of interest. This is essential for
expressing NS4B because the basal expression of this
protease may lead to plasmid instability and cell death.
In particular, PET102/D-TOPO provides N-terminal
His-Patch thioredoxin for increased translation effi-
ciency and solubility of heterologous proteins. It also
provides one-step purification of NS4B in native
buffers without urea and chaotic agents in order to pro-
vide the possibility of refolding the recombinant pro-
tein which may play an important role in the
immunoreactivity of NS4B due to natural conforma-
tion of the epitopes. BL21 strain of E. coli (DE3) per-
mits high-yield expression of the recombinant protein
because BL21 Star (DE3) carries a mutated rne gene
that encodes a truncated RNase E resulting in an
increase in mRNA stability.
Most papers did not emphasize on the high yield of
the recombinant protein. However, we obtained
approximately 1 mg purified NS4B from 1 liter of
IPTG induced cell culture. Furthermore, most reports
did not analyze the immunoreactivity of the recombi-
nant NS4B. To our knowledge, only Sillanpaa et al.
(2009) analyzed the immunoreactivity of three struc-
tural and six non-structural HCV proteins including
NS4B produced in Sf9 insect cells by using the bac-
ulovirus expression system (5). Based on western blot
analyses, this study reported that NS4B was recog-
nized in 86% of patient sera, which is consistent with
85% sensitivity obtained from ELISA here. 
We have previously expressed and purified hepati-
tis C virus NS3 protease, NS5A protein and NS3 heli-
case fragment using directional TOPO vector
pET102/D-TOPO. 
In conclusion, the directional TOPO cloning pro-
vides an efficient and easy method for cloning and
expression of recombinant HCV NS4B. The direction-
al TOPO cloning should be evaluated for production of
other viral proteins. 
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